Nanotech 2008 Vol. 2
Nanotech 2008 Vol. 2
Nanotechnology 2008: Life Sciences, Medicine & Bio Materials - Technical Proceedings of the 2008 NSTI Nanotechnology Conference and Trade Show, Volume 2

Drug & Gene Delivery Systems Chapter 4

Toward in vivo Targeting Delivery of siRNA for Efficient Cancer Therapy

Authors: O. Taratula, P. Kirkpatrick, R. Salva, I. Pandya, T. Minko, H. He

Affilation: Rutgers-Newark University, United States

Pages: 346 - 349

Keywords: siRNA, delivery, extracellular, steric, lateral stability

There is an increasing enthusiasm for developing therapies based on RNA interference (RNAi). However, the main obstacle in siRNA therapy is RNA delivering to the cytoplasm where it can guide sequence-specific mRNA degradation. An efficient, nontoxic delivery strategy has not been developed yet. Attempts to develop effective nonviral vectors for in vivo delivery of nucleic acids through a systemic route are hampered by difficulties of combining of high extracellular stability with ready availability of the nucleic acids following entry into cells. Here we report a targeted siRNA delivery vector that display good extracellular stability and intracellular bioavailability for efficient gene silencing. SiRNAs were packaged into discrete nanoparticles by polypropyleneimine dendrimers. Modification of the siRNA nanoparticles with dithiol containing crosslinker and further PEGylation of crosslinked condensates provided their sterical and lateral stabilization. In order to specifically delivery the siRNA nanoparticles to cancer cells, the distal end of PEG was modified with a targeting agent, such as LHRH. The enhancement of the internalization of LHRH modified condensates was demonstrated. The ability of the delivered siRNA to silence their targeted mRNA was shown by PCR experiment. We envision this approach can be used in vivo systematic delivery of siRNAs for efficient cancer therapy.

Toward in vivo Targeting Delivery of siRNA for Efficient Cancer Therapy

ISBN: 978-1-4200-8504-4
Pages: 808
Hardcopy: $159.95